Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post operative pain, has commenced dosing.
Innocoll’s BUPIVACAINE SURGICAL IMPLANT is a biodegradable and fully bioresorbable matrix [...]